Tousif K, Saeed S, Hamid S, Haider T, Basit J, Rauf Khalid A
Ann Med Surg (Lond). 2023; 85(5):1594-1600.
PMID: 37228986
PMC: 10205331.
DOI: 10.1097/MS9.0000000000000121.
Kandula U, Tuji T, Gudeta D, Bulbula K, Mohammad A, Wari K
J Blood Med. 2023; 14:159-187.
PMID: 36855559
PMC: 9968437.
DOI: 10.2147/JBM.S397722.
Chavda V, Bezbaruah R, Dolia S, Shah N, Verma S, Savale S
Process Biochem. 2023; 127:66-81.
PMID: 36741339
PMC: 9886570.
DOI: 10.1016/j.procbio.2023.01.018.
Lanza F, Monaco F, Ciceri F, Cairoli R, Sacchi M, Guidetti A
Hematol Oncol. 2022; 40(5):857-863.
PMID: 35932208
PMC: 9538413.
DOI: 10.1002/hon.3060.
Seghatchian J, Pereira P, Lanza F
Transfus Apher Sci. 2022; 61(6):103499.
PMID: 35811273
PMC: 9250817.
DOI: 10.1016/j.transci.2022.103499.
COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.
Hervig T, Flesland O, Nissen-Meyer L
Transfus Apher Sci. 2022; 61(4):103487.
PMID: 35778352
PMC: 9188440.
DOI: 10.1016/j.transci.2022.103487.
Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.
Agrawal A, Jha T, Gogoi P, Diwaker P, Goel A, Khan A
Transfus Apher Sci. 2022; 61(6):103455.
PMID: 35618641
PMC: 9090870.
DOI: 10.1016/j.transci.2022.103455.
The use of convalescent plasma therapy in the management of a pregnant woman with COVID-19: a case report.
Moura L, Liao A, Negrini R, Zlotnik E
Einstein (Sao Paulo). 2022; 20:eRC6550.
PMID: 35195192
PMC: 8809646.
DOI: 10.31744/einstein_journal/2022RC6550.
Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma.
Schneider M, Emmenegger M, Xu C, Morales I, Meisl G, Turelli P
Life Sci Alliance. 2021; 5(2).
PMID: 34848436
PMC: 8645332.
DOI: 10.26508/lsa.202101270.
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders.
Lanza F, Agostini V, Monaco F, Passamonti F, Seghatchian J
Clin Hematol Int. 2021; 3(3):77-82.
PMID: 34820612
PMC: 8486975.
DOI: 10.2991/chi.k.210403.001.
Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial.
Khamis F, Al Arimi Z, Al Naamani H, Al Bahrani M, Pandak N, Al Bolushi Z
Oman Med J. 2021; 36(5):e296.
PMID: 34631155
PMC: 8491110.
DOI: 10.5001/omj.2021.105.
Assessment of severity and mortality of COVID-19 with anti-A1 and anti-B IgM isohaemagglutinins, a reflection of the innate immune status.
Ozcelik F, Tanoglu A, Guven B, Keskin U, Kaplan M
Int J Clin Pract. 2021; 75(11):e14624.
PMID: 34251730
PMC: 8420313.
DOI: 10.1111/ijcp.14624.
V483A: an emerging mutation hotspot of SARS-CoV-2.
Ashwaq O, Manickavasagam P, Haque S
Future Virol. 2021; .
PMID: 34194534
PMC: 8223177.
DOI: 10.2217/fvl-2020-0384.
Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda.
Muttamba W, Lusiba J, Namakula L, Byakika-Kibwika P, Ssali F, Ddungu H
PLoS One. 2021; 16(6):e0252306.
PMID: 34138909
PMC: 8211202.
DOI: 10.1371/journal.pone.0252306.
A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.
Fatima N, Kaushik V, Ayoub A
Iran J Med Sci. 2021; 46(3):151-168.
PMID: 34083848
PMC: 8163704.
DOI: 10.30476/ijms.2020.86417.1624.
Efficacy of convalescent plasma therapy in severe COVID-19 patients.
Akay Cizmecioglu H, Goktepe M, Demircioglu S, Tekinalp A, Cizmecioglu A, Tuna A
Transfus Apher Sci. 2021; 60(4):103158.
PMID: 33994106
PMC: 8106203.
DOI: 10.1016/j.transci.2021.103158.
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.
Peng H, Rhind S, Beckett A
JMIR Public Health Surveill. 2021; 7(4):e25500.
PMID: 33825689
PMC: 8245055.
DOI: 10.2196/25500.
Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
Gontu A, Srinivasan S, Salazar E, Surendran Nair M, Nissly R, Greenawalt D
Commun Biol. 2021; 4(1):267.
PMID: 33627795
PMC: 7904946.
DOI: 10.1038/s42003-021-01813-y.
Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions.
Putter J
Transfus Apher Sci. 2021; 60(2):103093.
PMID: 33610448
PMC: 7881713.
DOI: 10.1016/j.transci.2021.103093.
People with blood disorders can be more vulnerable during COVID-19 pandemic: A hypothesis paper.
Aydemir D, Ulusu N
Transfus Apher Sci. 2021; 60(3):103080.
PMID: 33608217
PMC: 7874911.
DOI: 10.1016/j.transci.2021.103080.
